While we certainly cannot exclude that the efficacy of a liver-selective class IIa HDAC knockdown on improving glucose metabolism and reducing gluconeogenesis might have been more pronounced in mouse models of type 2 diabetes, we decided not to replicate our siRNA approach in such a disease model. Here, HDAC9 is linked to type 2 diabetes mellitus.